Table 3. Proportion of Variability in Clinic-Level Percentages of Patients Provided Diabetes-Related Preventive Services Accounted for by Clinic-Level Patient Panel Characteristics
Clinic Patient Panel CharacteristicsFull Patient Panel*Restricted Patient Panel
LDLFLUMicro-AlbHbA1cLDLFLUMicro-AlbHbA1c
Model r2
    Mean age0.21§0.120.010.20§0.22§0.160.020.30§
    Minority race0.120.060.55§0.080.120.060.51§0.02
    English-speaking0.020.100.010.010.040.060.010.02
    Spanish-speaking0.030.030.08<0.010.060.010.080.01
    No insurance0.25§0.18§<0.010.29§0.25§0.18§<0.010.25§
    Continuous insurance0.26§0.18§<0.010.31§0.25§0.18§<0.010.28§
    Income <50% of FPL0.040.150.020.060.030.150.010.08
Change in model r2
    Mean age0.01<0.010.02<0.010.020.020.030.05
    Minority0.13§0.070.55§0.100.120.060.48§0.02
    English-speaking0.010.070.01<0.010.010.110.01<0.01
    Spanish-speaking0.010.080.090.010.010.070.050.02
    Average income <50% of FPL0.020.030.030.020.020.02<0.010.03
  • Values were estimated using regression models of the logit transformation of the percentage of the patient panel receiving services.

  • * Includes all diabetic patients meeting inclusion criteria of at least 1 visit in 2006 and 2007; 425 patients were included in multiple clinic panels.

  • Each patient was assigned to only one clinic denominator.

  • Proportion of variability accounted for by clinic-level patient panel characteristics (unadjusted).

  • § P < .05.

  • Any patient with a race other than “white.” This includes black, Asian, Native American, Pacific Islander, nonwhite, and “other race.”

  • The difference between the r2 of a model containing the listed patient characteristic and the percentage of patients with continuous insurance and the r2 of a model containing only the percentage of patients with continuous coverage. Changes in r2 were not reported for the percentage of patients with no insurance because of the high correlation of the measure with the percentage of patients continuously insured.

  • FPL, Federal poverty level; FLU, influenza vaccination; HbA1c, hemoglobin A1c monitoring; LDL, low-density lipoprotein cholesterol screening; Micro-Alb, urine microalbumin screening.